Effects of Astaxanthin on Oxidative Stress
in Overweight and Obese Adults
|
Choi HD et al. ? This study revealed that supplemental astaxanthin (ASX) for 3 weeks improved oxidative stress biomarkers by suppressing lipid peroxidation and stimulating the activity of
the antioxidant defense system. Methods
Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties. |
Other articles in Internal Medicine>> Click here to see the complete listParental overweight/obesity, social factors, and child overweight/obesity at 7 years of age Cardiovascular risk factors attributable to obesity and overweight in Switzerland |
Dementia in Parkinsons
Disease Current Treatment Options in Neurology, 04/14/11 |
Kurtz AL et al. ? Parkinsonian motor signs that are accompanied by clinically significant cognitive impairment should be treated with carbidopa/levodopa only, as dopamine agonists and other
antiparkinsonian medications generally carry a higher risk of provoking or exacerbating psychotic symptoms. Minimizing sedating medications during the day and promoting nocturnal sleep may
help the daytime sleepiness; melatonin, clonazepam, gabapentin, and possibly memantine may be useful in treating REM sleep behavior disorder. Orthostatic hypotension can be managed with
various nonpharmacologic interventions, and if needed, fludrocortisone and pyridostigmine. Midodrine should be used cautiously, if at all.
Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties. |
Other articles in Internal Medicine>> Click here to see the complete listAlmitrine-Raubasine combination for dementia Ventricular dilatation and brain atrophy in patients with Parkinsons disease with incipient
dementia How to evaluate quality of care from the perspective of people with dementia: An overview of the
literature |
Your Article SummaryRhythm- and Rate-Controlling Effects of Dronedarone in Patients With Atrial Fibrillation (from the ATHENA Trial)The American Journal of Cardiology, 03/29/11 |
Richard L. Page et al. - Dronedarone demonstrated both rhythm- and rate-controlling properties in ATHENA and reduced the risk for first cardiovascular hospitalization or death from any
cause. The effects are likely to contribute to the reduction of important clinical outcomes observed in this trial. Methods
Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties. |
Other articles in Internal Medicine>> Click here to see the complete listDronedarone for atrial fibrillation: How does it compare with amiodarone Irbesartan in Patients with Atrial Fibrillation Irregular Heart Beat Plus Stroke May Increase Dementia Risk |
Your Article SummaryCalcium Citrate and Vitamin D in the Treatment of OsteoporosisClinical Drug Investigation, 04/07/11 |
Quesada Gomez JM et al. ? Calcium citrate formulations taken between meals may help to prevent abdominal distension and flatulence, as well as minimize the risk of renal calculus formation,
thus helping to optimize patient compliance. Therefore, calcium citrate combined with vitamin D is the combination of choice for the prevention or treatment of osteoporosis.
Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties. |
Other articles in Internal Medicine>> Click here to see the complete listUse of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their
relationship with duration of the disease and chronic complications Role of zoledronic acid in the prevention and treatment of osteoporosis |
Your Article SummaryTreatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE USOsteoporosis International, 04/15/11 |
Barrett-Connor E et al. ? Lower treatment satisfaction was associated with a 22% (1/0.82) to 67% (1/0.60) increased risk of discontinuation/switching osteoporosis medication during 1 year
of follow-up. Methods
Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties. |
Other articles in Internal Medicine>> Click here to see the complete listBisphosphonates for postmenopausal osteoporosis Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic
post-menopausal women Lasofoxifene: Selective estrogen receptor modulator for the prevention and treatment of postmenopausal
osteoporosis |
Your Article SummaryDenosumab and bisphosphonates: Rivals or potential partners? A hybrid molecule hypothesisMedical Hypotheses, 04/12/11 |
Anastasilakis AD et al. – The authors hypothesize that bisphosphonates could serve as a vehicle for the delivery of denosumab selectively to the skeleton. Thus, the effect on the
immune system could be minimized, along with a potential increase in the antiresorptive efficacy, as a result of the combined action of denosumab and the bisphosphonate on the earlier and
later stages of osteoclast life, respectively.
Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties. |
Other articles in Internal Medicine>> Click here to see the complete listUse of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis Calcium Citrate and Vitamin D in the Treatment of Osteoporosis Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their
relationship with duration of the disease and chronic complications |
Your Article SummaryUndertreatment of osteoporosis in persons with dementia? A population-based studyOsteoporosis International, 04/18/11 |
Haasum Y et al. ? The results indicate an undertreatment of osteoporosis in persons with dementia, although osteoporotic fractures are common among these patients. Methods
Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties. |
Other articles in Internal Medicine>> Click here to see the complete listUse of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results
from POSSIBLE US Calcium Citrate and Vitamin D in the Treatment of Osteoporosis |
Your Article SummaryAliskiren vs. Angiotensin Receptor Blockers in Hypertension: Meta-Analysis of Randomized Controlled TrialsAmerican Journal of Hypertension, 04/21/11 |
Gao D et al. - Aliskiren is as effective as angiotensin receptor blockers (ARBs) (losartan, valsartan, and irbesartan) in controlling blood pressure (BP) and does not differ from ARBs in
risk of adverse events. Methods
Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties. |
Other articles in Internal Medicine>> Click here to see the complete listAge-dependent gender differences in hypertension management Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer
patients Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive
crisis |
No comments:
Post a Comment